Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 4,637 matching trials from the live ClinicalTrials.gov search.

Filters: Los Angeles, California Clear all

Conditions: Abdominal Aortic Aneurysm
Interventions: Decision aid; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Neuroendocrine Tumors in Lung
Interventions: Lanreotide (Autogel formulation), Placebo, Best Supportive Care; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 14
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 11 more

Conditions: Hereditary Angioedema (HAE)
Interventions: ecallantide; Drug
Lead sponsor: Shire; Industry
Eligibility: 16 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 40
States / cities: Little Rock, Arkansas • Bell Gardens, California • Granada Hills, California + 35 more

Conditions: Acquired Immunodeficiency Syndrome
Interventions: Investigational BD FACSPresto System, BD FACSCalibur flow cytometer, Sysmex hematology analyzer KX-21; Device
Lead sponsor: Becton, Dickinson and Company; Industry
Eligibility: Not listed
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • San Jose, California

Conditions: Grade 2 Meningioma, Grade 3 Meningioma, Recurrent Meningioma
Interventions: Biospecimen Collection, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Stereotactic Radiosurgery; Procedure · Biological · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 29
States / cities: Phoenix, Arizona • Duarte, California • La Jolla, California + 23 more

Conditions: Wilson Disease
Interventions: UX701, Standard of Care (SOC); Genetic · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • Sacramento, California + 9 more

Conditions: Stroke
Interventions: Detailed feedback, Basic feedback; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Node Positive HER2 Negative Breast Cancer
Interventions: Placebo, Aspirin; Other · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 69 Years
Enrollment: 3,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1426
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 902 more

Conditions: Plaque Psoriasis
Interventions: TAK-279, Placebo, Apremilast; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 693 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Fremont, California + 24 more

Conditions: Bladder Cancer
Interventions: Hexaminolevulinate hydrochloride (HCL), Karl Storz D-Light C Photodynamic Diagnostic (PDD) system; Drug · Device
Lead sponsor: Photocure; Industry
Eligibility: 18 Years and older
Enrollment: 4,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2028
U.S. locations: 23
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more

Conditions: Alzheimer Disease
Interventions: Rofecoxib, Naproxen; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 55 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Irvine, California + 34 more

Conditions: Prediabetic State, Atherosclerosis, Metformin
Interventions: Metformin XR, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 7,410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Childhood Medulloblastoma
Interventions: Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine; Procedure · Drug · Other + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 4 Years to 21 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 106
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more

Conditions: Electronic Cigarette Use
Interventions: RELX ENDS Tobacco Flavor 1, RELX ENDS Tobacco Flavor 2, RELX ENDS Menthol Flavor 1, RELX ENDS Menthol Flavor 2; Other
Lead sponsor: Cheerain HK Limited; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Burbank, California

Conditions: HIV Infections, H1N1 Influenza Virus
Interventions: Influenza A (H1N1) monovalent vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 29
States / cities: Alhambra, California • La Jolla, California • Long Beach, California + 22 more

Conditions: Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions: Gammaplex; Biological
Lead sponsor: Bio Products Laboratory; Other
Eligibility: 2 Years to 16 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 8
States / cities: Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more

Conditions: Smoking, Endothelial Dysfunction
Interventions: Electronic hookah vaping with nicotine, Electronic hookah vaping without nicotine; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 39 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Milk Allergy
Interventions: Experimental Extensively Hydrolyzed Formula, Active Comparator Formula; Other
Lead sponsor: Perrigo Nutritionals; Industry
Eligibility: Up to 13 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 15 more

Conditions: Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
Interventions: VRx-3996 and valganciclovir; Combination Product
Lead sponsor: Viracta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 22
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 15 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab; Drug · Biological
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 889
States / cities: Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 593 more

Conditions: Congenital Heart Diseases, Cardiac Diseases
Interventions: Not listed
Lead sponsor: Matthias Stuber; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Neoplasm
Interventions: EP2101; Biological
Lead sponsor: Epimmune; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 8
States / cities: Los Angeles, California • Orlando, Florida • Albany, New York + 5 more

Conditions: Osteogenesis Imperfecta
Interventions: Not listed
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2031
U.S. locations: 11
States / cities: Phoenix, Arizona • Los Angeles, California • Wilmington, Delaware + 8 more

Conditions: Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Rhabdomyosarcoma, Sclerosing Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma
Interventions: Cyclophosphamide, Dactinomycin, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Questionnaire Administration, Radiation Therapy, Temsirolimus, Vincristine Sulfate, Vinorelbine; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 355
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 210 more

Search by objective public record fields.

Preferences for Open Vs. Endovascular Repair for Abdominal Aortic Aneurysm

Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours

Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema

Accuracy Evaluation of the BD FACS Presto System

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

Pedaling Exercises for Disability and Activity Limitations

Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Blue Light Cystoscopy With Cysview® Registry

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

Use Behavior, Nicotine Uptake, and Subjective Effects Comparison of Tobacco and Menthol e-Liquids by ENDS Consumers

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

Electronic Hookah and Endothelial Cell Function

Formula for Children With Cow's Milk Allergy

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)

An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer

BBD Longitudinal Study of Osteogenesis Imperfecta

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma